Brussels (Belgium), 27 September, 2013 (CET) 11h00 - regulated information

UCB SA (NYSE Euronext UCB) has just announced an offering of around EUR 300 million senior unsecured bonds, due January 2021 (the "Bonds"), to be issued under its EUR 3 billion EMTN Programme.

The Bonds will be sold to qualified institutional investors across Europe. The transaction is conducted by Barclays, CA-CIB and The Royal Bank of Scotland plc, acting as Global Coordinators and Active Joint Bookrunners and Santander and Mitsubishi UFJ Securities, acting as Active Joint Bookrunners for the offering. The issue and delivery of the Bond is expected to take place on October 4th, 2013.

This offering follows a series of pan-European bond investor meetings held from Monday 23rd, September until Thursday 26th, September.

The Bonds will mature on January 4th, 2021.

UCB expects to announce the final terms of the offering of the Bonds at pricing, scheduled to take place today.

This press release does not constitute an offer to sell or a solicitation to buy any securities, and the offer of the Bonds by UCB does not constitute a public offering.

For further information

Antje Witte, Investor Relations, UCB
T +32 2 559 9414, antje.witte@ucb.com

Alexandra Deschner, Investor Relations UCB
T: +32 2 559 9683, alexandra.deschner@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual

distributed by